Document is current
Any future updates will be listed below
-
Authors
Kwaśny, Aleksander
Wilkowska, Alina
Pastuszak, Michał
Pastuszak, Krzysztof
Cubała, Wiesław Jerzy
-
Funding
Funding for this research was provided by:
Gdański Uniwersytet Medyczny (01-10026 / 0010396/ 01/ 221 / 221/ 0 / 2026;)
- License Information
-
More Information
Article History
Received: 17 February 2026
Revised: 4 May 2026
Accepted: 7 May 2026
First Online: 20 May 2026
Declarations
:
: Krzysztof Pastuszak has no conflict of interestMichał Pastuszak received research support from Beckley Psytech, Compass Pathways, Definium Therapeutics, GH Research, MSD. Aleksander Kwaśny received research support from Beckley Psytech, Compass Pathways, Definium Therapeutics, GH Research, MSD. Alina Wilkowska has received research support from Angelini, Biogen, Eli Lilly and Company, Janssen- Cilag, Lundbeck, Polpharma, Sanofi, Termedia, Valeant, Bristol Myers Squibb.Wiesław Jerzy Cubała has received grants: Acadia, Alkermes, Allergan, Angelini, Auspex Pharmaceuticals, Beckley Psytech, BMS, Celon, Cephalon, Compass Pathways, Cortexyme, Ferrier, Forest Laboratories, GedeonRichter, GH Research, GWPharmaceuticals, HMNC Brain Health, IntraCellular Therapies, Janssen, KCR, Lilly, Lundbeck, MindMed (Definium), Minerva, MSD, NIH, Neumora, Novartis, Orion, Otsuka, Recognify Life Sciences, Sanofi, Seaport, Servier; Honoraria: Adamed, Angelini, AstraZeneca, BMS, Celon, GH Research, GSK, Janssen, KRKA, Lekam, Lundbeck, Minerva, NeuroCog, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, Zentiva; Advisory boards: Angelini, Celon (ended 2021), Douglas Pharmaceuticals, GH Research, Janssen, MSD, Novartis, Polpharma, Sanofi, Tasman Therapeutics.
